Key Takeaways

  • Alcon and RxSight have entered a non-exclusive collaboration to develop adjustable presbyopia-correcting IOLs by combining Alcon's IOL designs with RxSight's light-adjustable technology
  • The companies aim to create a postoperative adjustable PCIOL platform that enables surgeons to refine visual outcomes after cataract surgery

Alcon and RxSight announced they have entered into a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting IOLs (PCIOLs), combining each company's technologies to expand customization options for patients undergoing cataract surgery.

Under the agreement, the companies will integrate RxSight's postoperative light-adjustable lens technology with Alcon's presbyopia-correcting intraocular lens optical designs. The goal is to create a co-developed platform that enables surgeons to fine-tune visual outcomes after cataract surgery for patients who choose a presbyopia-correcting IOL. 

Under the terms of the agreement, RxSight will receive a $60 million upfront payment to initiate development activities. The company is eligible to receive up to an additional $140 million upon achievement of specified development and regulatory milestones.

Alcon will lead global commercialization of any resulting products, while RxSight will be responsible for development and manufacturing. RxSight will also receive royalties based on net sales.

"Our leading PCIOLs have helped millions of patients reduce or eliminate the need for glasses after cataract surgery," said David J. Endicott, CEO of Alcon, in a company statement. "Together with RxSight's technology, we have the opportunity to develop tunable PCIOLs, giving surgeons even greater confidence to refine outcomes after surgery."

"We are excited to work with Alcon to provide patients greater access to outcomes customized to their needs after surgery," said Ron Kurtz, president and CEO of RxSight. "This collaboration underscores our belief in the importance of adjustability and will help accelerate its expansion across a wider base of patients."